LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique …

ALAMEDA, Calif.--(BUSINESS WIRE)--

LifeMap Sciences, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), announced today that according to Google Analytics, the Companys databases have attracted over two million unique visitors in the previous 12 months. Since the announcement of the acquisition of Xennex in May 2012, LifeMap launched LifeMap Discovery, a database resource for stem cell research, and MalaCards, a database with nearly 17,000 human disease entries. These assets, combined with GeneCards, a compendium of human genes, provide an integrated database suite with diverse commercial opportunities in science and medicine. LifeMap Sciences holds the exclusive worldwide license to market GeneCards and MalaCards from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science. LifeMap Discovery is a database owned and developed by LifeMap Sciences. In this update, LifeMap describes the nature of its current users, and outlines for the first time its goals for 2013 in marketing products to this user base.

According to Google Analytics, the sites have generated more than 2,000,000 unique visitors with more than 13,000,000 page views in the past 12 months. LifeMap clients and partners include dozens of large, fee-paying pharmaceutical and biotechnology companies, as well as leading government patent offices, and its products are used free of charge by scientists at more than a thousand academic institutions worldwide.

LifeMap achievements since the last update include:

Key goals for 2013 include:

In recognition of the large and growing number of life sciences and medical professionals using our database suite, we plan to roll out a series of additional resources that will include subscription and pay-for-use products. We will continue our support of academic researchers with free products to meet their career and research needs, said David Warshawsky, PhD, CEO of LifeMap. By leveraging our leading resources and large user base, we look forward to realizing LifeMaps potential for significant revenue growth.

We are witnessing the unification of the fields of genomics, cell biology, and medicine, said Michael West, PhD, CEO of BioTime and Chief Scientific Officer of LifeMap. As a result, professionals in one field increasingly require instant access to large amounts of data from the other fields. LifeMap is fulfilling BioTimes strategic goals, on the one hand by generating near-term revenue to balance the longer-term nature of our cell-based therapies, and on the other by building foundational tools integral to the future of medicine.

About LifeMap Sciences, Inc.

LifeMap Sciences (www.lifemapsc.com) core technology and business is based on its integrated database suite, the discovery platform for biomedical and stem-cell research. This platform includes GeneCards, the leading human gene database; LifeMap Discovery, the database of embryonic development, stem cell research and regenerative medicine; and MalaCards, the human disease database. LifeMap Sciences also markets PanDaTox, an innovative, recently developed, searchable database that can aid in the discovery of new antibiotics and biotechnologically beneficial products.

In addition to database offerings, LifeMap Sciences is BioTimes principal internet marketing subsidiary for research products, including PureStem human progenitor cell lines, GMP human embryonic stem (hES) cell lines, ESpan growth media for progenitor cell lines, and cell differentiation media for non-therapeutic uses, via its LifeMap BioReagents portal. LifeMap Sciences utilizes its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

See more here:
LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique ...